OVERVIEW
Immune checkpoint inhibitors and EGFR-TKIs, which have shown efficacy in advanced lung cancer, are now being applied to perioperative treatment. Many agents are expected to be introduced into the perioperative treatment of resectable Stage IB to Stage III, but the balance of efficacy and adverse events varies for each subset of patients. In using each agent in clinical practice, the debate continues as to whether a new perioperative therapy should be recommended for all patients or for a subset of patients. In this webinar, we would like to deepen the discussion on immune checkpoint inhibitors in the perioperative setting.

This is the joint webinar between IASLC and JLCS (Japan Lung Cancer Society, https://www.haigan.gr.jp/). This webinar will consist of a 20-minute presentation from the keynote speaker, Dr. Enriqueta Felip, given in English, followed by a 25-minute panel discussion conducted in Japanese with 15-minutes at the end for Q&A. This webinar is designed to meet the educational needs of physicians and researchers specializing in medical oncology, thoracic surgery, and radiation oncology. To meet the needs of both international and Japanese audiences, the keynote will be provided in English and the panel discussion in Japanese.

Hidehito Horinouchi, MD, PhD
Assistant Chief of the Department of Thoracic Oncology
National Cancer Center Hospital

Yasuhiro Tsutatni, MD, PhD
Department of Surgical Oncology
Research Institute for Radiation Biology and Medicine Hiroshima University

At the end of the webinar, learners will be able to:
1. understand current standards of perioperative treatment in resectable NSCLC
2. understand candidates for future standard therapy of perioperative treatment
3. discuss appropriate indication of perioperative treatment including immune checkpoint inhibitors